90 related articles for article (PubMed ID: 6250340)
1. Inhibitors of angiotensin-converting enzyme.
Cushman DW; Ondetti MA; Cheung HS; Antonaccio MJ; Murthy VS; Rubin B
Adv Exp Med Biol; 1980; 130():199-225. PubMed ID: 6250340
[No Abstract] [Full Text] [Related]
2. Effects of captopril in animal models of hypertension.
Antonaccio MJ; Rubin B; Horovitz ZP
Clin Exp Hypertens (1978); 1980; 2(3-4):613-37. PubMed ID: 7000464
[No Abstract] [Full Text] [Related]
3. Effect of the angiotensin-converting enzyme inhibitor, captopril, on development of renal hypertension in rats.
Fregly MJ; Lockley OE; Simpson CE
Pharmacology; 1981; 22(5):277-85. PubMed ID: 7019935
[No Abstract] [Full Text] [Related]
4. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
Lebel M; Rodrigue ME; Agharazii M; Larivière R
Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril.
Aono J; Koga T; Yamazaki T; Shiraki Y; Sakai K
Arch Int Pharmacodyn Ther; 1988; 292():203-22. PubMed ID: 3293542
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of angiotesin-converting enzyme by quercetin alters the vascular response to brandykinin and angiotensin I.
Häckl LP; Cuttle G; Dovichi SS; Lima-Landman MT; Nicolau M
Pharmacology; 2002 Aug; 65(4):182-6. PubMed ID: 12174832
[TBL] [Abstract][Full Text] [Related]
7. Effects of captopril and bradykinin on arterial pressure in rats with mestranol-induced hypertension.
Johnson JA; Dostal DE
Contraception; 1986 Sep; 34(3):303-10. PubMed ID: 3539511
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of angiotensin-converting enzyme.
Cushman DW; Ondetti MA
Prog Med Chem; 1980; 17():41-104. PubMed ID: 6273970
[No Abstract] [Full Text] [Related]
9. Hormonal responses to angiotensin blockade. Comparison between receptor antagonism and converting enzyme inhibition.
Johnston CI; Millar JA; Casley DJ; McGrath BP; Matthews PG
Circ Res; 1980 Jun; 46(6 Pt 2):I128-34. PubMed ID: 6247084
[No Abstract] [Full Text] [Related]
10. Role of bradykinin receptors in the renal effects of inhibition of angiotensin converting enzyme and endopeptidases 24.11 and 24.15 in conscious rabbits.
Tomoda F; Lew RA; Smith AI; Madden AC; Evans RG
Br J Pharmacol; 1996 Sep; 119(2):365-73. PubMed ID: 8886422
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421.
Cohen ML; Kurz KD
J Pharmacol Exp Ther; 1982 Jan; 220(1):63-9. PubMed ID: 6273529
[No Abstract] [Full Text] [Related]
12. Inhibition of angiotensin-converting enzyme by des-Leu10-angiotensin I: a potential mechanism of endogenous angiotensin-converting enzyme regulation.
Snyder RA; Wintroub BU
Biochim Biophys Acta; 1986 May; 871(1):1-5. PubMed ID: 3008847
[TBL] [Abstract][Full Text] [Related]
13. Development of specific inhibitors of angiotensin I converting enzyme (kininase II).
Cushman DW; Cheung HS; Sabo EF; Rubin B; Ondetti MA
Fed Proc; 1979 Dec; 38(13):2778-82. PubMed ID: 228989
[No Abstract] [Full Text] [Related]
14. [A new point of attack for the treatment of hypertension; captopril, an orally active inhibitor of the enzymatic conversion of angiotensin I into angiotensin II].
Schalekamp MA; de Bruyn JH; Wenting GJ; Man in 't Veld AJ; Derkx FH
Ned Tijdschr Geneeskd; 1980 Nov; 124(47):1996-2003. PubMed ID: 6255350
[No Abstract] [Full Text] [Related]
15. [Effect of inhibition of converting enzyme by captopril on arterial pressure, renin and aldosterone in essential hypertension].
Posadas C; Sánchez G; Boyer JL; Delmar M; Serrano PA
Arch Inst Cardiol Mex; 1982; 52(4):295-300. PubMed ID: 6291470
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme inhibitors: pathogenic and therapeutic implications for arterial hypertension.
Waeber B; Brunner HR; Wauters JP; Gavras H
Adv Nephrol Necker Hosp; 1981; 10():111-33. PubMed ID: 6267906
[No Abstract] [Full Text] [Related]
17. Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
Johnson AL; Price WA; Wong PC; Vavala RF; Stump JM
J Med Chem; 1985 Nov; 28(11):1596-602. PubMed ID: 2999393
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of the protective effect of angiotensin-converting enzyme inhibition in hemorrhagic shock.
Trachte GJ; Lefer AM
Proc Soc Exp Biol Med; 1979 Oct; 162(1):54-7. PubMed ID: 228313
[No Abstract] [Full Text] [Related]
19. Synthesis and pharmacological screening of new angiotensin converting enzyme inhibitors.
Gubert S; Braso MA; Sacristán A; Ortiz JA
Farmaco; 1990 Jan; 45(1):59-79. PubMed ID: 2186741
[TBL] [Abstract][Full Text] [Related]
20. Prolongation by captopril of action potential duration in the normal and hypertrophied rat ventricle: direct action or inhibition of the local angiotensin converting enzyme?
Ribuot C; Cardinal R; Gouin L; Moreau P; Godin D; Vermeulen M; de Champlain J; Rochette L; Nadeau R
Cardiovasc Res; 1994 Feb; 28(2):221-7. PubMed ID: 8143304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
